The FDA approved the first mRNA flu shot. It landed a year to the day after the U.S. defunded the technology behind it.

On Aug. 5, 2025, the Department of Health and Human Services terminated 22 mRNA vaccine development projects and roughly $500 million in federal investment in the technology, a base that can be retargeted at different diseases, citing the science. Thirty-six days earlier, on June 30, 2025, Moderna had already published the Phase 3 readout of its mRNA seasonal flu vaccine: a 26.6% advantage over a standard flu shot in 40,805 adults across 11 countries, with the benefit holding in patients over 65 (STAT News).

On Aug. 5, 2026, the FDA approved that vaccine as mFlusiva, the first mRNA seasonal influenza vaccine ever licensed in the United States. The anniversary landing on the same day as the cancellation is a coincidence. The 36-day gap between the public data and the policy is not.

The approval rests on the same Phase 3 readout that was sitting in plain view when HHS pulled the funding. Moderna's June 30, 2025 release reported the 26.6% relative improvement over a licensed standard-dose comparator in 40,805 adults across 11 countries, a study size large enough to detect the kinds of subgroup effects regulators care about, including adults 65 and older, where the mRNA advantage held. That dataset is what the FDA's Vaccines and Related Biological Products Advisory Committee reviewed.

VRBPAC voted unanimously, twice, that mFlusiva's benefits outweigh its risks: first in adults 50 to 64, then in adults 65 and older. "Nine independent experts, appointed by this government, could not produce a single vote against it," Coller wrote in STAT News, summarizing the vote record. The committee's only function is to advise the agency. The agency followed it.

The road between the Phase 3 readout and the approval was not straight. On Feb. 3, 2026, the FDA issued a refusal-to-file letter on Moderna's application. The letter was signed personally by Vinay Prasad, then head of the agency's vaccines evaluation center. Prasad's sole stated objection: the trial used a standard-dose comparator rather than a high-dose flu shot, the kind typically given to adults 65 and older. Fifteen days later, after a meeting and public outcry, the FDA reversed the refusal. No new evidence entered the record. The reversal cleared the way for the August approval.

European, Canadian, and Australian regulators accepted the identical application without the same objection, according to the column. A non-U.S. reviewer with a different comparator philosophy would have been a meaningful policy debate. Three non-U.S. reviewers raising no objection at all is harder to read as a science call.

The defunding also touched programs the Phase 3 readout could not speak to. A June 2026 five-year update on individualized mRNA therapy combined with pembrolizumab in high-risk melanoma reported a 49% reduction in recurrence or death and a 59% reduction in distant metastasis. An April 2026 Memorial Sloan Kettering Phase 1 in pancreatic cancer found that roughly 90% of patients whose immune systems responded to a personalized mRNA vaccine were alive up to six years after their final dose; five-year survival in the disease is normally about 13%. That result needs a larger randomized trial, the kind HHS cut.

Outside the canceled federal pipeline, the technology is still moving. KJ Muldoon, a child treated for a rare disease caused by a single spelling error in his DNA, received the first custom gene-editing therapy built for his specific mutation. The editor reached his liver as mRNA inside a lipid nanoparticle, the same chemistry the HHS pullout defunded. The FDA proposed a rare-disease pathway in February 2026 that runs through the same technology. Private capital and Chinese programs continue to advance the platform, and the United States is the only major country described in the column as walking away.

Coller disclosed in STAT News that he is a co-founder of the Alliance for mRNA Medicines. The mRNA-against-Covid work, designed with NIH and paid for by HHS, has been credited in Lancet and Commonwealth Fund analyses with preventing more than 3 million American deaths in its first two years. None of that disqualifies the data trail. It qualifies who is reading it.

The next test of whether the defunding was a science call or a calendar collision will be the next mRNA vaccine the FDA sees from a defunded pipeline. The platform's clinical pipeline is long. Federal funding for it is not.